ImmunityBio completes Phase I safety trial of autologous M-ceNK cell therapy combined with ANKTIVA

 

• Large-scale NK2022/2023 manufacturing programs successfully completed to support ImmunityBio's NK cell therapy platform development.
• New NCI-led preclinical efficacy data support further clinical development of the autologous M-ceNK cell therapy with ANKTIVA.
• Milestones designed to advance ImmunityBio's NK cell platform into further clinical development.

https://finviz.com/quote.ashx?t=IBRX&p=d